Human Immunoglobulin (IVIg/SCIg) Manufacturing

About Lyric Bio

Lyric Bio is a private, pre-clinical stage biotech founded in 2021 and based in Cambridge, USA, developing a disruptive manufacturing platform for complex biologics. The company's core technology involves laser-printed cellular substrates that enable ultra-high-density cell growth in small-scale bioreactors, aiming to produce over 1,000 doses of immunoglobulin from a single donor versus the current industry standard of approximately 10 plasma donations per dose. By moving from a donation-based supply chain to a controlled, scalable manufacturing process, Lyric seeks to address critical issues of cost, supply stability, and quality in the global Ig market. The company is led by its co-founders, CEO Kayj Shannon and CSO Dr. Melanie Matheu.

Therapeutic Areas